Creating Tomorrow's Immunotherapies NXI therapeutics focuses on the research and development of a new generation of selective immunosuppressive drugs for autoimmune diseases and transplantations - with objectives of high efficacy, good safety without adverse effects as seen with conventional immunosuppressants.

169 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing a new generation of vaccines and immunotherapeutic drugs Virometix is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases

150 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Affirma Biotech develops new products to overcome the challenge of Multi Drug Resistant and Chronic Infections Affirma Biotech is a start-up company specialized in the discovery and development of new anti-infective drugs via immunomodulation.

165 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

less complexity. more biology. At Chromodynamics, we are on a mission to deliver instruments that eliminate guesswork from drug development and prescription. Our unique technology allows for an enormous improvement in speed, efficacy, and cost with which exciting new treatments like immunotherapy are developed. We have been recognised as one of the most promising startups in the Eindhoven Brainport region and are expanding our team to ramp up our product development. Imaging systems, Multispectral imaging, Real-time analysis, Chemical imaging, Spectroscopy, Scientific instruments, Contract research, and Data analysis

931 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Valora Therapeutics is a privately held biotech, co-founded with Carolyn Bertozzi, developing multispecific antibodies and T cell engagers that break the glyco-immune checkpoint. Our proprietary AbLecTM and T-LecTM platforms combine precise tumor targeting with localized glyco-immune checkpoint disruption to generate therapeutics with superior anticancer activity without the requirement for delivering toxic payloads. Valora's discovery engine was built on a $30M Seed Round led by Avalon BioVentures.

185 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

125 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

260 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Platelet Secretome : a New Therapeutic Strategy Against Neurodegeneration InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.

158 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

372 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Galvani Bioelectronics is a joint venture between GSK and Verily Life Sciences. We are devoted to the development of life changing neuromodulation therapies for patients with chronic disease. Medical Devices

103 similar entities Type: SMB Activities: deeptech healthtech Technologies: Synthetic Biology

Improving health and life for people living with diabetes, obesity and other cardiometabolic diseases Arecor is a clinical-stage biotech company, developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases. Superior Products for Diabetes Treatment, Liquid Products with Superior Stability, Lyo-to-liquid switch, IV to SC switch, High Concentration mAbs, Ready-to-Use (RTU) Formats, Differentiated Biosimilars, Vaccine Stability, and Oral Delivery of Peptides

206 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Creating a new path for neurodegenerative diseases Tetraneuron is a drug discovery company, focused on the development of a disruptive gene therapy for Alzheimer’s Disease (AD) and an Early Biomarker for this neurodegenerative condition. alzheimer, terapia genica, gene therapy , disruptive therapy, Alzheimer´s Disease, Biomarker, neurodegenerative disease, neuroscience, neurociencia, enfermedades neurodegenerativas, neurodegeneration, dementia, and pioneering

138 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing Breakthrough Cancer Immunotherapies Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. Cancer Immunotherapies, Phosphatases, Immuno-Oncology, Checkpoint inhibitors, CAR-T, and Solid tumours and Lymphomas

344 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Memo Therapeutics AG, an Ipsen company, is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections.

215 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

MImAbs is an innovative start-up specialized in immunotherapy. Our goal is to develop monoclonal antibodies in cancer and inflammatory diseases for third parties (academics, pharmacuetical companies, biotechnologies, etc.) Anticorps monoclonaux, Immuno-pharmacologie, Génération et bioproduction d'anticorps, and Génération d'immunoconjugués

227 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug

228 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovation for your health and well-being. Pharmaceutical company, R&D oriented dedicated to the development and marketing of senolytic compounds, food supplements and drugs against aging, age-related degenerative diseases and cancer.

81 similar entities Type: SMB Activities: deeptech biotech healthtech Technologies: Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

359 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

OneHealth/AI DeepTech discovering patentable mixes of natural ingredients preserving health and optimizing bioprecesses Alphanosos, a Green One-Health DeepTech company, uses its own Artificial Intelligence algorithms to discover, develop and market active ingredients and products based on blends of extracts from non-pharmaceutical ingredients, in particular edible plants. These active mixtures, some of which are already patented in 15 countries for their antimicrobial activities, are intended for the animal hygiene, dermocosmetics, food preservation and cosmetics sectors, bioprocess optimization and in the longer term, for functional foods and disease treatments. The company began its Research and Development (R&D) activities in mid-2015 and is …

224 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I.

Precision treatment of immune disorders Polyneuron is a growing Basel-based biotechnology company active in the area of autoimmune disease treatments. The company was founded in 2014 as a spinout company from the University of Basel to develop novel treatments to combat immune disorders using its Antibody-CatchTM technology platform. The company currently employs about 10 people and has raised a significant amount in equity funding from top-tier VCs. We are a team of passionate and experienced scientists, entrepreneurs and investors willing to bring new therapies to patients.

176 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Altevax is developing a disruptive immunotherapy technology against cancer Altevax is a Phase 2 clinical-stage biotechnology company developing a pioneering melanin-based immunotherapy platform for cancer treatment. Its patented technology enhances antigen-specific T-cell immune responses and is compatible with a broad range of peptides, with potential to complement existing immuno-oncology approaches, including anti-PD-1 therapies. Altevax’s lead program targeting TERT in glioblastoma is currently in Phase 2 clinical development. The company collaborates with leading clinical institutions, including AP-HP, and is actively fundraising and exploring strategic partnerships to accelerate development. Cancer vaccines, immunotherapy, melanin, therapeutic vaccines, Peptidic vaccines, infectious diseases, CD8 Killer T …

219 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Modulating T-regulatory cells to balance immunity Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

137 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

InBrain Pharma, a CNS disorders focused biotech, founded in 2018, exploiting through an exclusive worldwide patent license signed with the Northern France TTO, a groundbreaking therapeutic approach of advanced Parkinson’s Disease based on the research work of Pr David DEVOS and Pr Caroline MOREAU developed within their academic research Team from the Université́ de Lille, Lille Neuroscience & cognition UMR-S 1172 INSERM and the Lille University Hospital. To date, the company has raised €4.4 million in dilutive and non-dilutive financing, these funds having enabled to carry out a first phase I/IIb DIVE-I clinical trial on 12 patients, for which results …

130 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic ImCheck Therapeutics an @Ipsen company designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. antibodies, immuno-oncology, Immune checkpoint Modulators, Auto-immunity, innate immunity, oncology, cancer, precision-based medicine, adaptative immunity, EVICTIONtrial, ICT01, and gamma-deltaTcells

246 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Crossing the next frontier, to give you a fair chance to fight Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. Our novel candidates harness microbiome-associated innate immune regulatory mechanisms. Inflammatory Bowel Diseases, Live Biotherapeutics, Microbiome, Immunotherapies, Immuno-oncology, and Immuno-inflammation

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovation. Applied. Founded in 2021, POLYGON Therapeutics is a Paris-based biotechnology company developing precision cardio-immunology therapies targeting inflammatory drivers of cardiovascular disease. The company combines translational human biology, biomarker-driven development and immunology expertise to develop novel therapeutic approaches in cardiovascular disease.

228 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

French biotech company targeting the Adipocyte to treat insulin resistance, type 2 diabetes and associated comorbidities AdipoPharma is a French biotech company with a US subsidiary committed to understanding the role of the adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis. Our first-in-class candidate - PATAS - is set to enter clinical trials later this year.

91 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

565 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The network of bioproduction biotherapies integrators (RIBB) aims to coordinate, lead and assist the 8 integrators in the field of biotherapies and bioproduction, labeled as part of the “biotherapies and bioproduction of innovative therapies” (SABB) acceleration strategy so that they can respond to their technological platform missions on behalf of academic or industrial partners, and facilitate the industrialization of their technologies/products. Biotherapies, Bioproduction, Cell Therapy, Gene Therapy, and Extracellular Vesicles

209 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Adding Quality Years of Life We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

113 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Digital bio-solutions designed to support the development of biomedicines and optimize their prescription. mYXpression is an innovative French company positioned in the field of health innovation. The company, specialized in R&D, develops innovative tools to assist in the prescription of biomedicines. Its first tool, the RITI® RA test, provides a personalized report specific to the patient by indicating an efficacy score for each biotherapy. This brand new approach provides numerous useful insights to the doctor by assisting in the prescription of biotherapy in order to increase the patient's chances of remission. bio-numérique, innovation technologique, big data, bio-technologie , biotherapie, intelligence …

189 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I.

Pioneering therapies based on aptamer technology aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept. Biopharmaceutical, Biotechnology, Aptamers, Immunology, Stroke, and Inflammatory diseases

390 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A new hope for patients affected by Alzheimer’s disease CaSRevolution is a research company specialized in devising innovative therapies for neurodegeneration diseases We have discovered a new mechanism that explains the progression of Alzheimer’s Disease and identified a potential therapeutic approach biotech, neurodegeneration, startup, and alzheimer

129 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Reversing Neurodegeneration - Restoring Life GeneCode is developing small-molecule drugs that bind and activate GDNF (Glial cell line-Derived Neurotrophic Factor) receptors for the treatment of Parkinson’s disease (PD) and other neurodegenerative conditions.

119 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovating to Enhance Quality of Life Fitabeo Therapeutics is a clinical-stage specialty pharmaceutical company that develops and commercialises a differentiated portfolio of innovative medicines focusing on indications where existing treatments are inadequate for the target population. It deploys breakthrough technologies to develop medicines that enable patient autonomy, decentralise patient care and provide superior health outcomes. Oral Thin Films, Geriatrics, Paediatrics, Patient autonomy, Equitable Access, Innovative medicines, Medication adherence, Central Nervous System, Women's Health, and Neurology

616 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Curileum is intervening early in serious gastrointestinal (GI) disease development with novel diagnostics & therapeutics Curileum is intervening early in serious GI disease development with novel therapeutics to detect and correct cell production in the gut mucosa Biotechnology

143 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

630 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We believe that everyone - irrespective of who they are or where they live - deserve medications that work We believe that everyone - irrespective of who they are or where they live - deserve medications that work

310 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. biotechnology, pharmaceuticals, drug discovery, preclinical research, bioanalytical development services, bioinformatics, systems biology, proteins, genomics, proteomics, autoimmune disorders, regulatory studies, medicinal chemistry, agrochemical, industrial chemistry, and assay development&screening

514 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Harnessing the Power of Tumor Gene Therapy to Turn the Tide in the Battle Against Cancer Headquartered in Cambridge, Massachusetts, Akamis Bio is a clinical-stage oncology company developing systemically administered immunotherapies to treat solid tumors, initially in patients with locally advanced rectal cancer (LARC). Its proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform is designed to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, with its lead clinical-stage program, NG-350A, driving intratumoral expression of a CD40 agonist monoclonal antibody. To learn more, please visit www.akamisbio.com Immuno-oncology and Re-programming the Tumor Microenvironment

113 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry

535 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Une entreprise spécialisée dans le développement de thérapies transformatrices ayant un impact sur la longévité. Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging. Our small molecules are aimed at stimulating biological resilience to stress during aging. Ruvembri - in regulatory and clinical phases - is our leading drug candidate is administered orally: • for the treatment of severe respiratory events related to COVID-19 following positive results in Phase 2/3 clinical study (COVA) • for the treatment of reduced mobility in elderly patients with sarcopenia, …

263 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Treating Neurodegenerative Disease by Restoring Autophagy At Samsara Therapeutics, we’re on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases. Our innovative approach aims to delay the progression of several debilitating conditions, offering new possibilities for patients and their families. biotechnology, biopharmaceuticals, rare disease, neurodegeneration, longevity, drug discovery, and drug development

428 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science for cure. NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden. Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy. Biopharmaceutical company, Immunotherapy, and Immuno-oncology

299 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Redefining Synthetic Lethality beyond HRD Tessellate BIO discovers and develops novel precision oncology medicines with the mission to turn cancer patients into cancer survivors. A private preclinical stage biotechnology company, Tessellate BIO is redefining Synthetic Lethality by developing drugs that target unexplored or difficult to drug pathways beyond HRD. Headquartered in the Netherlands and with research labs at the Stevenage Bioscience Catalyst, UK, Tessellate BIO is supported by top-tier life science investors BioGeneration Ventures (BGV) and Forbion. drug discovery, precision oncology, and biotechnology

67 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Exploiting a new class of tumour specific antigens for cancer therapy A newly established NewCo developing therapeutics targeting a novel class of tumour-specific antigen. TCR-T cells, Immuno-oncology, Vaccines, Bi-specifics, Splicing, Epigenetics, Oncology, T cell biology, and Antigen presentation

178 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Ilya Pharma 🇸🇪🇺🇸 is bringing local-acting immunotherapies to patients Delivering local-acting immunotherapies to patients ATMP, Gene Therapy, Drug development, Clinical trials, GMP, IBD, Wound treatment, Scar, Topical, Oral, Research, Science, Immunology, Immunophysiology, microbiology, Applied microbiology, Regulatory excellence, Skin, Diabetes, IBD, Cysticfibrosis, SAVI, colitis, Cystic fibrosis, and Inhalation

646 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class solutions for unmet health and personal care needs Results through innovation. We are an innovative biotechnology group with two divisions. Our consumer health arm has commercial products for the personal care market addressing nail, skin, scalp and hair issues. NovaBiotics pharma division has advanced clinical-stage product candidates for medically unmet, life-limiting inflammatory, infectious and respiratory disease. Our highly disruptive solutions to personal care and health needs address significant global markets. biotechnology, biologics, infectious disease, and drug discovery & development

225 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

business development mission in Life Sciences IVD Cosmetic finding new customers finding new partners BtoBioInnovation offers outsourced services in Marketing & Business Development in Life Sciences, Biotech, Molecular Diagnostics, Cosmetic, Nutraceutical : - Operational Marketing : representation on Trade shows, congresses, Seminar organisation - E-Marketing: E-mailing Campaign, Google Analytics, webinars - Strategic Business Development: Chinese Market, Trends in oncology, Neurology, Biomarkers, Molecular Diagnostics, coaching for Negociation & Due Diligence, Analysis of Pharma & Biomedical Industries. - Operational Business Development: Identify & qualify new customers, partners, distributors, Sourcing licensing opportunities, Marketing, Business development, Biotech, Life sciences, In vitro diagnostics, Cosmetic, Nutraceutical, …

222 similar entities Type: SMB Activities: martech biotech Technologies: Synthetic Biology

Working at the frontier of microfluidics, automation and machine learning to accelerate cell-based medicines. Scaled Biolabs accelerates the discovery and development of complex cell-based medicines, such as stem cell therapies and cancer immunotherapies. Their full stack optimization engine reduces complexity and time to market, by leveraging high-throughput, micro-scale cell culture, automation, and deep data insight. It also powers internal, grant funded programs such as developing a new gold standard for manufacturing dopaminergic neurons to treat Parkinson’s disease. Microfluidics, Biomedical R&D, Bioreactor, Single-cell Biology, Bioengineering, Stem Cells, Tissue Engineering, Cell Culture, Cell-based Assays, machine learning, and computer vision

170 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. - Image Processing A.I. Synthetic Biology A.I. - Machine Learning

Genetic Medicine Delivered BreezeBio is a biotechnology company developing precision genetic medicines enabled by targeted, non-viral delivery across biologically relevant tissues. Using our proprietary NanoGalaxy® platform, we engineer nanoparticles designed to deliver genetic payloads, including mRNA, to specific cell types. Our platform has demonstrated delivery to immune cells as well as select tissues in the heart, lung, and central nervous system. We are advancing an internal therapeutic pipeline focused on autoimmune diseases and oncology. Our lead program, BRZ-101, is designed to restore immune tolerance in type 1 diabetes and is advancing into IND-enabling studies. BreezeBio is headquartered in the South …

140 similar entities Type: Startup Activities: biotech deeptech nanotech Technologies: Synthetic Biology

We envision molecules for epilepsy and longevity: Research and development of novel patentable structures. Bicoll is an expert in bioactive plant-derived small molecules with outstanding expertise in high-tech natural product chemistry and validated experience in medicinal chemistry. Currently Bicoll focuses on two main fields such as neurodegenerative disorders (primarily, epilepsy) and longevity. In both of the fields it develops own preclinical candidates. Drug Discovery Services, Custom Synthesis, Medicinal Chemistry Services, Natural Product, Plant-based compounds, Food supplements, Nutraceuticals, and Cosmetics

63 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Better Access. Better Lives. Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars. Biopharmaceuticals, Research and Development, Biosimilars, Biotechnology, Pharmaceutical, Biogenerics, Health, Cell Line Development, Business Development, and Regulatory

418 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis

582 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Technology-driven biotech with an AI-powered miniprotein RnD platform VRG Tx is technology-driven biotech with a drug discovery platform that integrates AI with wet lab processes to develop next-generation therapeutics. Our vision is to cure diseases through previously undruggable targets and inaccessible mechanisms of action. medicinal biotechnology, research, immunology autoimmune deases , translational health research, use of genetic engineering in medicine, anti cancer drug discovery, oncological drugs, autoimmune diseases, translational research, peptide, cellandgenetherapy, and genetherapy

589 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The Uniqueness of Individualized Neoantigen Cancer Vaccine to Reshape the Future of Early-Stage Cancer Treatment Cancer immunotherapy Transgene (Euronext: TNG) is a clinical-stage biotechnology company focused on individualized therapeutic vaccines

166 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Precision Radiotherapy From Within BetaGlue Therapeutics is a clinical stage oncology company that has developed an advanced radiotherapy platform enabling localised targeted treatment of both unresectable solid tumours and also treatment of surgical resection margins called YntraDose. radiotherapy, nuclear medicine, oncology, and medical devices

207 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Targeting Genetically Defined Cancers Beactica Therapeutics is a specialist drug discovery and development company, committed to the fight against cancer. Beactica is advancing a proprietary pipeline of first-in-class therapeutics by applying its molecular interaction-based drug discovery engine synergistically across multiple small molecule modalities – including allosteric modulators, protein–protein interaction inhibitors and targeted protein degraders (PROTACs). Surface Plasmon Resonance (SPR), Fragment-Based Drug Discovery, Interaction Analysis, Kinetics, Mechanism of action, Oncology, PROTACs, Allosteric Modulators, Therapeutics, and Drug Discovery

123 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology